Search

Displaying results 1911 - 1920 of 10000 in total
  1. Drug

    Nateglinide

    go.drugbank.com/drugs/DB00731
    Approved

    Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). … Meglitnides may have a neutral effect on weight or cause a slight increase in weight.

    Categories: Drugs Used in Diabetes
  2. Drug

    Zotepine

    go.drugbank.com/drugs/DB09225
    ApprovedWithdrawn

    In the EMA, by 2015 it was under pharmacovigilance studies for the potential treatment of acute renal failure.[L1314] … [A31855] It has been used as an antipsychotic in Japan, India and some places in Europe like UK and Germany since 1980's.[A31857] Zotepine was never approved by the FDA.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  3. Drug

    Huperzine A

    go.drugbank.com/drugs/DB04864
    ApprovedInvestigationalWithdrawn

    The botanical has been used in China for centuries for the treatment of swelling, fever and blood disorders. Recently in clinical trials in China, it has demonstrated neuroprotective effects. … It is currently being investigated as a possible treatment for diseases characterized by neurodegeneration – particularly Alzheimer’s disease.

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    Vanzacaftor

    go.drugbank.com/drugs/DB18373
    ApprovedInvestigational

    [L52275,A179677] Vanzacaftor was first approved by the US FDA in December 2024 in combination with another CFTR corrector - [tezacaftor], which binds to a different site than vanzacaftor - and [deutivacaftor … ], a CFTR potentiator, for the treatment of patients with responsive CFTR mutations.

    Synonyms: VX-121
  5. Drug

    Padeliporfin

    go.drugbank.com/drugs/DB15575
    ApprovedInvestigational

    [A244699] Padeliporfin was first approved by the European Commission on November 10, 2017, for the treatment of low-risk prostate cancer in adults meeting certain clinical criteria.[L39799] … Padeliporfin is a water-soluble chlorophyll derivative and cytotoxic photosensitizer used for vascular-targeted photodynamic therapy for malignancies.

    Categories: Sensitizers Used in Photodynamic/radiation Therapy, Heterocyclic Compounds with 4 or More Rings
  6. Drug

    Empagliflozin

    go.drugbank.com/drugs/DB09038
    ApprovedInvestigational

    Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. … [A203453] It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 diabetes mellitus.

    Mixtures: Synjardy XR, Synjardy XRCategories: Drugs Used in Diabetes
  7. Drug

    Fenoldopam

    go.drugbank.com/drugs/DB00800
    Approved

    A dopamine D1 receptor agonist that is used as an antihypertensive agent. It lowers blood pressure through arteriolar vasodilation.

    Categories: Antihypertensive Agents Indicated for Hypertension
  8. Drug

    Brexanolone

    go.drugbank.com/drugs/DB11859
    ApprovedInvestigational

    As of March 2019, brexanolone - developed and made available commercially by Sage Therapeutics Inc. as the brand name product Zulresso - is the first drug to have ever been approved by the US FDA specifically … for the treatment of postpartum depression (PPD) in adult females [F4066].

  9. Drug

    Foreskin fibroblast (neonatal)

    go.drugbank.com/drugs/DB10770
    Approved

    Dermagraft has only been available in the United States as an investigational device (IDE). Dermagraft for the treatment of diabetic foot ulcers was approved for sale in Canada in 1997. … If wound closure is achieved, it is likely to delay the need for surgical intervention and provide other benefits such as improvements in productivity, mental outlook, social interactions, and time at

  10. Drug

    Gallium Ga-68 gozetotide

    go.drugbank.com/drugs/DB16019
    ApprovedInvestigational

    [L43542] In December of the same year, the drug was fully authorized by the EMA.[L44682] In Octer 2022, Ga-68 PSMA-11 was approved by Health Canada for diagnostic use in men with prostate cancer. … In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended Ga-68 gozetotide be granted marketing authorization for the diagnosis of prostate cancer.

    Synonyms: (68)Ga Labeled Glu-NH-CO-NH-Lys(ahx)-hbed-CCCategories: Compounds used in a research, industrial, or household setting